

Application of Multifunctional Targeting Epirubicin Liposomes in the Treatment of Non-Small-Cell Lung Cancer [Corrigendum]

Song X, Ju R, Xiao Y, et al. *Int J Nanomedicine*. 2017;12:7433–7451.

The authors apologize for this error and advise it does not affect the results of the paper.

The authors have advised due to an error at the time of figure assembly, Figure 5 on page 7442 is incorrect. The correct Figure 5 is shown below.




Figure 5 Destructive effects on VM channels and blocking effects on LLT cells migration in vitro after treatment with varying formulations.

Notes: (A) Destructive effects on VM channels, Magnification $\times 100$. (B) blocking effects on LLT cells migration. Magnification $\times 100$. a. Blank control; b. epirubicin liposomes; c. epirubicin plus honokiol liposomes; d. OCT-modified epirubicin liposomes; e. multifunctional targeting epirubicin liposomes.

Abbreviations: LL T, Lewis lung tumor; OCT, octreotide; VM, vasculogenic mimicry.